



**IMDRF** International Medical Device  
Regulators Forum

# **Regulatory Updates Health Sciences Authority, Singapore**

**Ms Wong Woei Jiuang**


**Asst Group Director,**

**Medical Devices Cluster,**

**Health Sciences Authority, Singapore**

**September 2023**

# COVID-19 Tests - Transition from Special Access to Full Registration



- All COVID-19 tests previously authorised under PSAR have been moved to full registration
- Any new COVID-19 test will go through the standard pre-market evaluation and full registration process applicable to all IVDs
  - PSAR will no longer be applicable
- Guide on the key validation requirements for **full registration** available online - [Validation Requirements for Product Registration of COVID-19 Diagnostic Tests – Self-Tests.](#)

# Manufacturing of dental devices in dental laboratories in Singapore

- **Dental laboratories** specialise in manufacturing or customising devices used by registered dentists to assist in providing oral health care to their patients.
  - In Singapore, these labs mainly manufacture “custom-made medical devices” that are mainly lower risk (class A and class B) dental devices such as crowns, bridges, dentures and orthodontic appliances following the prescription/written instruction from a registered dentist
  - Each unit of these dental devices is custom-made for an individual patient and does not fit others
  - The manufactured devices are supplied to the prescribing dentists, who fits the devices for their patients
- **Dental laboratories** in Singapore operate
  - Within MOH licensed facilities under the Healthcare Services Act (HCSA) such as healthcare institutions (e.g. National Dental Centre) and dental clinics; **OR**
  - As standalone set ups (i.e. private entities)
- **Standalone dental laboratories**, which operate outside hospitals and dental clinics, are not licensed by MOH
  - No regulatory oversight on these entities, their manufacturing and supply

# A titrated regulatory approach for manufacturing in dental laboratories

A risk calibrated regulatory approach based on the following considerations:

- i) These dental laboratories have been supporting the practice of dentistry by manufacturing custom-made dental MDs for over 40 years
- ii) To date, we have not come across any serious safety incidents associated with the custom-made dental devices (specific to an individual patient) manufactured in local dental laboratories
- iii) The manufacturing activity by these dental laboratories are mainly low risk:
  - They manufacture lower risk MDs (risk class A and B) and mainly custom-made dental MDs.
  - They manufacture the dental MDs solely based on a prescription or written instructions from a registered dentist to an individual patient and supply to these patients only through their dentists
  - There is professional oversight from a registered dentist in terms of prescribing and fitting of the dental MD

# A titrated regulatory approach for manufacturing in dental laboratories

- **Notification of Manufacturing:** All standalone dental laboratories manufacturing solely lower risk dental MDs (Class A and Class B) will be required to notify their local manufacturing site and their scope of activities via an online form to HSA.
  - They are required to implement and maintain a quality management system based on ISO 13485 and may be subject to random compliance audits by HSA.

***NOTE:** A standalone dental lab manufacturing higher risk MDs (Class C and D) will be subject to standard regulatory requirements i.e. a Manufacturer's licence requirement and ISO 13485 certification of their facility, with third party audit*

- **Product Notification for traceability:** Standalone dental laboratories will be required to notify the types of dental MDs (e.g. aligners, bridges) they manufacture to HSA prior to supply
- **Post-market Controls:** They will be subject to post-market reporting requirements (e.g. mandatory reporting of adverse events related to their MDs) and other duties and obligations (e.g. maintain manufacturing and distribution records, complaint records, ensure traceability of MDs manufactured)

# Medical Device Special Access Route – Strengthening Regulatory Oversight

- **Special Access Route (SAR):** Allows import and supply of unregistered medical device in order to meet unmet clinical needs or for compassionate use on patients upon request from a doctor
  - Requesting doctor must provide clinical justification to substantiate the clinical need
  - Not subject to the standard pre-market evaluation and registration process
- HSA implemented following additional measures to strengthen the oversight on SAR requests for unregistered medical devices in the interest of patient health and safety:

## Additional Measures

For **Class C and D** unregistered MDs

- Request for an unregistered MD must be endorsed by the Chairman, Medical Board (CMB) of the hospital; **and**

For specific categories of **Class D** unregistered MDs

- Prior approval is required from the Director-General of Health's (DGH) Office in MOH for the use of
  - New technologies and state-of-the-art medical devices, including novel indications for existing medical devices or technologies
  - Unregistered implants (e.g., pacemakers, breast implants)

# Guidance Documents – Key Updates

- Updated Guidance on Risk Classification of *In vitro* Diagnostic medical devices published in July 2023
  - Greater alignment to the IMDRF IVD risk classification guidance
- Updated Guidance on licensing of manufacturers, importers and wholesalers of medical devices published
  - MDSAP certificates accepted as an evidence of QMS for medical device manufacturers

□ Guidance documents and Guidelines can be accessed online at:

<https://www.hsa.gov.sg/medical-devices/guidance-documents>

# IMDRF GOOD REGULATORY REVIEW PRACTICES (GRRP) WORKING GROUP UPDATE

Dr. Lakshmidevi Balakrishnan, Health Sciences Authority (HSA), Singapore

Dr. Kenneth Cavanaugh, Food and Drug Administration (FDA), United States of America

**IMDRF 24<sup>th</sup> Session – Berlin, Germany**




# IMDRF GRRP Working Group Goals

- Develop documents focused on harmonizing marketing review requirements globally.
- Documents focus on:
  - Technical requirements for conducting marketing reviews
  - Competency requirements for marketing reviewers
  - Requirements for organizations performing marketing reviews




# GRRP Documents



**IMDRF GRRP WG/  
N40 FINAL:2017**  
*Competence, Training,  
and Conduct  
Requirements for  
Regulatory Reviewers*



**IMDRF GRRP WG/  
N47  
FINAL: 2018**  
*Essential Principles of  
Safety and  
Performance*



**IMDRF GRRP WG/  
N52 FINAL: 2019**  
*Principles of Labelling*

**Marketing Review Processes**


# GRRP Documents



IMDRF GRRP WG/  
N59 FINAL:2020  
*Requirements for  
Regulatory  
Authority  
Recognition of  
CABs*




IMDRF GRRP WG/  
N61 FINAL:2020  
*Assessment  
Methods for  
Recognition of CABs*



IMDRF GRRP WG/  
N63 FINAL:2020  
*Competence and  
Training  
Requirements for  
Assessors of CABs*



IMDRF GRRP  
WG/N66 FINAL:2021  
*Assessment and  
Decision Process for  
the Recognition of  
CABs Conducting  
Medical Device  
Regulatory Reviews*



IMDRF GRRP  
WG/N71 FINAL:2023  
*Medical Device  
Regulatory Review  
Report: Guidance  
Regarding Information  
to be Included*


## Recognition of Conformity Assessment Bodies (CABs)

## Benefits of GRRP WG Documents

- Promote consistency, predictability and transparency in regulatory marketing review programs through agreed-upon sets of criteria and processes
- Provide confidence that marketing regulatory reviews conducted by CABs are rigorous enough to meet the requirements of Regulatory Authorities
- Provide opportunities for convergence of marketing review requirements
- Benefit all regulators, even those just starting to develop a regulatory medical device marketing review system

# **Most Recent Work Item: N71 – Medical Device Regulatory Review Report: Guidance Regarding Information to be Included**

- Published in final on Feb 3, 2023
- Provides guidance regarding creation of a medical device regulatory review report
- A regulatory review report:
  - is a written record of the CAB’s determination of the extent of fulfillment of specified requirements;
  - captures, in a consistent manner, the evidence of a manufacturer’s conformity with the criteria for the regulatory review; and
  - will facilitate the exchange of information between RAs.
- Working group participation included CAB representatives as observers



## New Work Item

- A NWIP was approved in June 2023 to update previous GRRP documents for consistency with policy and terminology in most recently published GRRP document (IMDRF/GRRP WG/N71).
  - Changes needed in order to be consistent with and inclusive of the current approaches of several RAs
  - The GRRP WG reviewed existing GRRP documents and identified four that should be revised to ensure appropriate and consistent terminology throughout the all GRRP documents
  - The proposed changes to terminology demonstrate convergence among RAs toward a common language and concepts

### Goals:

To achieve consistent terminology to fulfill Priority 1 of the 2021-2025 IMDRF Strategic Plan: to develop a risk calibrated regulatory approach for innovations and promote harmonized pre-market review requirements for medical devices

## Documents to be Updated

- The GRRP WG reviewed existing GRRP documents and identified four that should be revised to ensure appropriate and consistent terminology throughout the all GRRP documents : N66, N61, N63, and N59
  - These changes require more than simple search and replace since careful consideration should be paid to which term is selected and how it is used based on the specific context
- References section of other GRRP documents will also be reviewed for updates
  - To ensuring date and language in references section is up to date

# Next Steps

- WG to review proposed edits and meet to discuss proposed edits from Sep- Dec 2023
- WG to submit documents for draft consultation to MC for consideration in Mar 2024
- Public consult of draft document in May 2024
- WG to deliberate comments and finalize changes by Oct 2024
- WG to submit final document for MC review in Dec 2024



# Thank you! Questions?

**Email**    [erin.cutts@fda.hhs.gov](mailto:erin.cutts@fda.hhs.gov)

---

**Disclaimer**

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright 2021 by the International Medical Device Regulators Forum.